quest diagnostics inc. - DGX
DGX
Close Chg Chg %
161.38 2.44 1.51%
Open Market
163.82
+2.44 (1.51%)
Volume: 322.93K
Last Updated:
Nov 21, 2024, 2:51 PM EDT
Company Overview: quest diagnostics inc. - DGX
DGX Key Data
| Open $161.03 | Day Range 160.33 - 164.25 |
| 52 Week Range 123.04 - 162.86 | Market Cap $18.01B |
| Shares Outstanding 111.62M | Public Float 111.06M |
| Beta 0.89 | Rev. Per Employee N/A |
| P/E Ratio 21.66 | EPS $7.52 |
| Yield 183.49% | Dividend $0.75 |
| EX-DIVIDEND DATE Jan 14, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 996.27K |
DGX Performance
| 1 Week | 0.55% | ||
| 1 Month | 4.05% | ||
| 3 Months | 5.05% | ||
| 1 Year | 19.02% | ||
| 5 Years | 52.32% |
DGX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
20
Full Ratings ➔
About quest diagnostics inc. - DGX
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
DGX At a Glance
Quest Diagnostics, Inc.
500 Plaza Drive
Secaucus, New Jersey 07940
| Phone | 1-973-520-2700 | Revenue | 9.25B | |
| Industry | Services to the Health Industry | Net Income | 850.00M | |
| Sector | Health Services | Employees | 48,000 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
DGX Valuation
| P/E Current | 21.656 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.33 |
| Price to Sales Ratio | 1.684 |
| Price to Book Ratio | 2.427 |
| Price to Cash Flow Ratio | 12.249 |
| Enterprise Value to EBITDA | 11.454 |
| Enterprise Value to Sales | 2.216 |
| Total Debt to Enterprise Value | 0.268 |
DGX Efficiency
| Revenue/Employee | 192,750.00 |
| Income Per Employee | 17,708.333 |
| Receivables Turnover | 7.646 |
| Total Asset Turnover | 0.689 |
DGX Liquidity
| Current Ratio | 1.307 |
| Quick Ratio | 1.202 |
| Cash Ratio | 0.378 |
DGX Profitability
| Gross Margin | 32.004 |
| Operating Margin | 14.602 |
| Pretax Margin | 12.214 |
| Net Margin | 9.187 |
| Return on Assets | 6.329 |
| Return on Equity | 13.934 |
| Return on Total Capital | 7.20 |
| Return on Invested Capital | 7.878 |
DGX Capital Structure
| Total Debt to Total Equity | 87.173 |
| Total Debt to Total Capital | 46.573 |
| Total Debt to Total Assets | 39.21 |
| Long-Term Debt to Equity | 77.898 |
| Long-Term Debt to Total Capital | 41.618 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Quest Diagnostics Inc. - DGX
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 9.44B | 10.79B | 9.88B | 9.25B | |
Sales Growth
| +22.15% | +14.32% | -8.39% | -6.38% | |
Cost of Goods Sold (COGS) incl D&A
| 5.82B | 6.65B | 6.54B | 6.29B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 361.00M | 408.00M | 437.00M | 439.00M | |
Depreciation
| 258.00M | 305.00M | 317.00M | 331.00M | |
Amortization of Intangibles
| 103.00M | 103.00M | 120.00M | 108.00M | |
COGS Growth
| +14.22% | +14.17% | -1.68% | -3.75% | |
Gross Income
| 3.61B | 4.14B | 3.35B | 2.96B | |
Gross Income Growth
| +37.52% | +14.55% | -19.15% | -11.53% | |
Gross Profit Margin
| +38.30% | +38.38% | +33.87% | +32.00% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.51B | 1.70B | 1.73B | 1.61B | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 1.51B | 1.70B | 1.73B | 1.61B | |
SGA Growth
| +7.17% | +12.39% | +1.71% | -6.67% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 66.00M | (304.00M) | 238.00M | 87.00M | |
EBIT after Unusual Expense
| 2.04B | 2.75B | 1.38B | 1.26B | |
Non Operating Income/Expense
| 11.00M | 3.00M | (1.00M) | 29.00M | |
Non-Operating Interest Income
| 3.00M | 1.00M | 10.00M | 11.00M | |
Equity in Earnings of Affiliates
| 8.00M | 56.00M | (55.00M) | 20.00M | |
Interest Expense
| 166.00M | 152.00M | 148.00M | 163.00M | |
Interest Expense Growth
| -7.78% | -8.43% | -2.63% | +10.14% | |
Gross Interest Expense
| 166.00M | 152.00M | 148.00M | 163.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 1.88B | 2.60B | 1.24B | 1.13B | |
Pretax Income Growth
| +75.09% | +37.95% | -52.48% | -8.50% | |
Pretax Margin
| +19.96% | +24.09% | +12.50% | +12.21% | |
Income Tax
| 460.00M | 597.00M | 264.00M | 248.00M | |
Income Tax - Current - Domestic
| 374.00M | 651.00M | 262.00M | 294.00M | |
Income Tax - Current - Foreign
| 1.00M | 3.00M | 1.00M | 3.00M | |
Income Tax - Deferred - Domestic
| 84.00M | (56.00M) | 2.00M | (48.00M) | |
Income Tax - Deferred - Foreign
| 1.00M | (1.00M) | (1.00M) | (1.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 8.00M | 56.00M | (55.00M) | 20.00M | |
Other After Tax Income (Expense)
| (6.00M) | (7.00M) | (4.00M) | (4.00M) | |
Consolidated Net Income
| 1.49B | 2.07B | 1.01B | 904.00M | |
Minority Interest Expense
| 68.00M | 85.00M | 69.00M | 54.00M | |
Net Income
| 1.43B | 1.99B | 942.00M | 850.00M | |
Net Income Growth
| +70.66% | +39.51% | -52.62% | -9.77% | |
Net Margin Growth
| +15.10% | +18.43% | +9.53% | +9.19% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 1.43B | 1.99B | 942.00M | 850.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 1.43B | 1.99B | 942.00M | 850.00M | |
EPS (Basic)
| 10.6791 | 15.904 | 8.1207 | 7.5893 | |
EPS (Basic) Growth
| +67.37% | +48.93% | -48.94% | -6.54% | |
Basic Shares Outstanding
| 134.00M | 125.00M | 116.00M | 112.00M | |
EPS (Diluted)
| 10.5221 | 15.5312 | 7.983 | 7.5221 | |
EPS (Diluted) Growth
| +67.37% | +47.61% | -48.60% | -5.77% | |
Diluted Shares Outstanding
| 136.00M | 128.00M | 118.00M | 113.00M | |
EBITDA
| 2.47B | 2.85B | 2.06B | 1.79B | |
EBITDA Growth
| +59.20% | +15.65% | -27.81% | -13.06% | |
EBITDA Margin
| +26.13% | +26.44% | +20.83% | +19.35% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 170.067 | |
| Number of Ratings | 20 | Current Quarters Estimate | 2.189 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 8.902 | |
| Last Quarter’s Earnings | 2.30 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 8.71 | Next Fiscal Year Estimate | 9.728 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 16 | 12 | 17 | 17 |
| Mean Estimate | 2.19 | 2.19 | 8.90 | 9.73 |
| High Estimates | 2.22 | 2.30 | 8.93 | 9.86 |
| Low Estimate | 2.11 | 1.90 | 8.86 | 9.65 |
| Coefficient of Variance | 1.32 | 4.56 | 0.18 | 0.62 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 6 |
| OVERWEIGHT | 2 | 3 | 1 |
| HOLD | 11 | 11 | 13 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Quest Diagnostics Inc. - DGX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Quest Diagnostics Inc. - DGX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 43,576 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $71.17 per share | 3,101,303.92 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 53,696 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $66.51 per share | 3,571,320.96 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 34,941 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $154.74 per share | 5,406,770.34 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 49,196 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $153.98 per share | 7,575,200.08 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 42,461 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $152.71 per share | 6,484,219.31 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 51,596 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $152.7 per share | 7,878,709.20 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 45,061 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $154.74 per share | 6,972,739.14 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | 40,130 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $154.03 per share | 6,181,223.90 |
| Nov 8, 2024 | Michael Joseph Deppe SVP, Corp. Controller & CAO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 4, 2024 | Timothy M. Ring Director | 15,721 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 27, 2024 | Mark A Gardner SVP of Molecular Gen & Oncol | 4,673 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $155.7 per share | 727,586.10 |
| Jul 19, 2024 | Sam A. Samad Executive Vice President & CFO | 17,446 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $142.65 per share | 2,488,671.90 |
| May 21, 2024 | Tracey C. Doi Director | 5,183 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Vicky B. Gregg Director | 17,892 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Robert B. Carter Director | 1,482 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Timothy L. Main Director | 25,094 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Gary M. Pfeiffer Director | 28,916 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Luis A. Diaz Director | 2,851 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Denise M. Morrison Director | 9,490 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |